Effects of nefopam on postoperative pain after ureteroscopic litholapaxy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0002178

Enrollment

120

Registered

2016-12-23

Start date

2016-08-03

Completion date

Unknown

Last updated

2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : The Nefopam premedication group received nefopam 40mg intravenously (IV) as premedication before induction, while the control group received 0.9&#37

saline 1.5 ml using unlabeled syringes for double blind.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patients were of age 18 to 70 and consisted of American Society of Anesthesiologists (ASA) physical status I and II, who were scheduled to receiving elective ureteroscopic removal of ureter stone and ureteral stent insertion.

Exclusion criteria

Exclusion criteria: Bladder outflow obstruction, overactive bladder (frequency greater than three times per night or more than eight times per 24 h), chronic kidney disease (serum creatinine > 1.6 mg/dL), chronic use of medication with anticholinergic effect (e.g., dimenhydrinate, tricyclic antidepressant), initial heart rate > 100 beats/min, asthma, morbid obesity (body mass index > 30 kg/m2), arrhythmia, heart failure, and psychiatric disease.

Design outcomes

Primary

Measure	Time frame
Catheter related bladder discomfort	—

Secondary

Measure	Time frame
Postoperative side effects/complications;Postoperative analgesic consumption;Incidence of catheter related bladder discomfort;Peak severity of catheter related bladder discomfort;Peak Numeric Pain Scale in PACU;Ramsay-Hunt sedation score	—

Countries

Korea, Republic of

Contacts

Public ContactHyung Rae Cho

Myongji Hospital

callmex@hanmail.net+82-31-810-6200

Outcome results